Mocetinostat (MGCD0103)

For research use only. Not for use in humans.

目录号：S1122 别名： MG0103

Mocetinostat (MGCD0103) Chemical Structure

CAS No. 726169-73-9

Mocetinostat (MGCD0103, MG0103) 是一种有效的HDAC抑制剂，对HDAC1抑制作用最强，无细胞试验中IC50为0.15 μM，比作用于HDAC2， 3，和11选择性高2到10倍，对HDAC4， 5， 6， 7，和8没有抑制活性。Mocetinostat (MGCD0103) 可诱导凋亡和自噬。Phase 2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1563.11	现货
5mg	RMB 1382.65	现货
50mg	RMB 6314.53	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达全国免运费分装免费

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Mocetinostat (MGCD0103)发表文献96篇：

Cancer Cell, 2021, S1535-6108(20)30662-0

PubMed: 33482121 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

J Clin Invest, 2022, e147908

PubMed: 35104240 ( click the link to review the publication )

Nat Commun, 2021, 12(1):5056

PubMed: 34417458 ( click the link to review the publication )

Cell Rep, 2021, 37(12):110129

PubMed: 34936867 ( click the link to review the publication )

Cancers (Basel), 2021, 13(15)3862

PubMed: 34359763 ( click the link to review the publication )

Signal Transduct Target Ther, 2021, 6(1):333

PubMed: 34482361 ( click the link to review the publication )

Cells, 2021, 10(11)3249

PubMed: 34831471 ( click the link to review the publication )

PLoS Genet, 2021, 17(11):e1009890

PubMed: 34723970 ( click the link to review the publication )

Rev Cardiovasc Med, 2021, 22(3):1037-1045

PubMed: 34565105 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0336

PubMed: 32978226 ( click the link to review the publication )

Sci Rep, 2020, 10(1):4337

PubMed: 32152395 ( click the link to review the publication )

Front Genet, 2020, 11:80

PubMed: 32158467 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:752

PubMed: 32850856 ( click the link to review the publication )

Biomed Res Int, 2020, 2020:4705615

PubMed: 32775424 ( click the link to review the publication )

Cancer Sci, 2020, 111(7):2374-2384

PubMed: 32391602 ( click the link to review the publication )

Acta Pharm Sin B, 2020, 10(4):615-627

PubMed: 32322466 ( click the link to review the publication )

J Cancer, 2020, 11(7):1915-1926

PubMed: 32194803 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

Cancer Discov, 2019, 9(4):526-545

PubMed: 30709805 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(1):185-195

PubMed: 30301863 ( click the link to review the publication )

Mol Oncol, 2019, 13(9):1944-1958

PubMed: 31225930 ( click the link to review the publication )
Pharmacol Res, 2019, 146:104281

PubMed: 31125601 ( click the link to review the publication )

ACS Omega, 2019, 4(22):19895-19904

PubMed: 31788622 ( click the link to review the publication )

Commun Biol, 2019, 2:272

PubMed: 31372511 ( click the link to review the publication )

EMBO Rep, 2018, 19(9)

PubMed: 30021835 ( click the link to review the publication )

Cancer Res, 2018, 78(20):5731-5740

PubMed: 30135193 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):381-392

PubMed: 28839000 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

JCI Insight, 2018, 3(22)125568

PubMed: 30429379 ( click the link to review the publication )

Curr Protoc Pharmacol, 2018, 81(1):e41

PubMed: 29927058 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(11):6334-6349

PubMed: 28369619 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

J Mol Cell Cardiol, 2017, 112:74-82

PubMed: 28886967 ( click the link to review the publication )

Biotechnol Bioeng, 2017, 114(11):2660-2667

PubMed: 28667749 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 361(1):140-150

PubMed: 28174211 ( click the link to review the publication )

Pain Physician, 2017, 20(5):E673-E685

PubMed: 28727712 ( click the link to review the publication )

Theriogenology, 2017, 87:298-305

PubMed: 27742403 ( click the link to review the publication )

Circ J, 2017, 82(1):192-202

PubMed: 28747611 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 8(4):6319-6329

PubMed: 28030834 ( click the link to review the publication )

Cell Death Discov, 2016, 2:16036

PubMed: 27551526 ( click the link to review the publication )

Mol Oncol, 2016, 10(5):735-750

PubMed: 26775640 ( click the link to review the publication )

ACS Chem Biol, 2016, 11(10):2685-2692

PubMed: 27459069 ( click the link to review the publication )

J Lipid Res, 2016, 57(5):868-81

PubMed: 27013100 ( click the link to review the publication )

Sci Rep, 2016, 6:38407

PubMed: 27910927 ( click the link to review the publication )
Am J Physiol Lung Cell Mol Physiol, 2016, 311(1):L124-34

PubMed: 27233998 ( click the link to review the publication )

J Biol Chem, 2016, 291(16):8745-55

PubMed: 26912657 ( click the link to review the publication )

Mol Cell Biol, 2016, 36(22):2838-2854

PubMed: 27573019 ( click the link to review the publication )

Future Med Chem, 2016, 8(13):1553-71

PubMed: 26971619 ( click the link to review the publication )

Cell Signal, 2016, 28(8):1015-24

PubMed: 27185186 ( click the link to review the publication )

Hypertens Res, 2016, 39(10):709-716

PubMed: 27278287 ( click the link to review the publication )

Nat Commun, 2015, 3;6:10091

PubMed: 26631872 ( click the link to review the publication )

Nucleic Acids Res, 2015, 10.1093/nar/gkv188

PubMed: 25769527 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(4):1014-23

PubMed: 25673820 ( click the link to review the publication )

Mol Oncol, 2015, 9(7):1447-1457

PubMed: 25957812 ( click the link to review the publication )

FEBS Lett, 2015, 589(10):1080-8

PubMed: 25816750 ( click the link to review the publication )

Oncotarget, 2015, 6(15):13757-71

PubMed: 25970771 ( click the link to review the publication )

Sheng Li Xue Bao, 2015, 67(5):447-54

PubMed: 26490061 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25784-800

PubMed: 26329759 ( click the link to review the publication )

Oncotarget, 2015, 6(32):33623-35

PubMed: 26378038 ( click the link to review the publication )

Oncotarget, 2015, 6(24):20449-65

PubMed: 26036259 ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(12):1375-85

PubMed: 26297712 ( click the link to review the publication )

Western University, 2015, Western University

PubMed: ( click the link to review the publication )

Blood, 2014, 123(10):1535-43

PubMed: 24449212 ( click the link to review the publication )

J Heart Lung Transplant, 2014, 33(6):644-53

PubMed: 24746638 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

J Neurosci, 2014, 34(17):6112-22

PubMed: 24760871 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1491

PubMed: 25341045 ( click the link to review the publication )

BMC Biol, 2014, 12:95

PubMed: 25406762 ( click the link to review the publication )
BMC Biol, 2014, 10.1186/1741-7007-12-30

PubMed: 24779377 ( click the link to review the publication )

Oncogenesis, 2014, 3:e127

PubMed: 25402609 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2014, 274(1):7-17

PubMed: 24200994 ( click the link to review the publication )

Cell Signal, 2014, 26(12):2912-20

PubMed: 25220405 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Fibrogenesis Tissue Repair, 2014, 7:10

PubMed: 25024745 ( click the link to review the publication )

Mol Cell, 2013, 52(3):406-20

PubMed: 24120667 ( click the link to review the publication )

Nat Struct Mol Biol, 2013, 20(3):317-25

PubMed: 23377543 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )

Oncogene, 2013, 33(5):653-64

PubMed: 23524580 ( click the link to review the publication )

J Neurosci, 2013, 33(17):7535-47

PubMed: 23616558 ( click the link to review the publication )

Pain, 2013, 154(9):1668-79

PubMed: 23693161 ( click the link to review the publication )

J Dent Res, 2013, 93(2):148-54

PubMed: 24334408 ( click the link to review the publication )

Mol Pharm, 2013, 10(1):307-18

PubMed: 23186311 ( click the link to review the publication )

J Am Heart Assoc, 2013, 2(5):e000317

PubMed: 24088507 ( click the link to review the publication )

Melanoma Res, 2013, 23(5):341-8

PubMed: 23963286 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Circ Res, 2012, 110(5):739-48

PubMed: 22282194 ( click the link to review the publication )

Oncogene, 2012, 32(33):3896-903

PubMed: 22945647 ( click the link to review the publication )

Biochem J, 2012, 447(3):457-64

PubMed: 22908849 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52095

PubMed: 23251689 ( click the link to review the publication )

Oncogene, 2011, 30(27):3062-72

PubMed: 21577204 ( click the link to review the publication )

J Biol Chem, 2011, 286(27):23842-51

PubMed: 21489983 ( click the link to review the publication )

PLoS One, 2011, 6(2):e17138

PubMed: 21359182 ( click the link to review the publication )

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述

靶点

HDAC1 ^[1] (Cell-free assay)	HDAC2 ^[1] (Cell-free assay)	HDAC11 ^[1] (Cell-free assay)	HDAC3 ^[1] (Cell-free assay)
0.15 μM	0.29 μM	0.59 μM	1.66 μM

体外研究

MGCD0103按剂量依赖性在纳摩尔浓度或低微摩尔浓度时只能抑制9个人类重组HDACs中的一部分，包括HDAC1, HDAC2, HDAC3, 和HDAC11。在体外，MGCD0103有效抑制人类HDAC1和HDAC2酶，但是不抑制二级HDACs。MGCD0103的外环氨基抑制酶时是必需的，因为作用于HDAC1和HDAC2的HDAC抑制活性已被desamino类似物全部消除。MGCD0103 6 μM时抑制活性达到最高状态，在HCT116细胞中MGCD0103最高抑制全部酶活的75%，而NVP-LAQ824抑制几乎达到100%。MGCD0103抑制A549细胞时也显示出剂量依赖性。^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
PBMC	MlnjRZBweHSxc3nzJGF{e2G7	M4LiRVAvPS9{L{Og{txO	NFGxb2ozPC92ODDo		MX\pcoR2[2W\|IHHwc5B1d3OrczDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODRyNkm0O{c,OjB2ME[5OFc9N2F-
HeLa	NX20d\|Y2TnWwY4Tpc44hSXO\|YYm=	MkjXNVAh\|ryPwrC=	NG\rW3A4KGh?	MoXwSG1UVw>?	NYiyUXVz\Gm\|coXweJMhdm:{bXHsJJNxcW6mbHWgZ4hm[2uyb3nueEBnfW6ldHnvci=>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODV\|OEi0NEc,OjB3M{i4OFA9N2F-
HeLa	NFvJT5lHfW6ldHnvckBCe3OjeR?=	NWTrXo5COTBizszNxsA>	NIrYUWI3NzF{L{K0JIg>	MV\EUXNQ	NGTudJJqdmS3Y3XzJI1qfG:2aXOgZYNkfW23bHH0bY9vKGGwZDDk[YxigWWmIICyNUBmgHC{ZYPzbY9v	NHfkTFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEWzPFg1OCd-MkC1N\|g5PDB:L3G+
HeLa	M1P3bWZ2dmO2aX;uJGF{e2G7	NUfXeGRYOC5\|LUGwJO69VQ>?	MYq4JIg>	NFnhRlBFVVOR	NGri[5BqdmO{ZXHz[ZMh[2G\|cHHz[UA{KGGwZDC3JIFkfGm4YYTpc44h\G:\|ZTDk[ZBmdmSnboTsfS=>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODV\|OEi0NEc,OjB3M{i4OFA9N2F-
HeLa	NUDPcplkTnWwY4Tpc44hSXO\|YYm=	MX[wMlMuOTBizszN	MX24JIg>	M2jCTGROW09?	NVvxcWU6cW6lcnXhd4V{KGGlZYT5cIF1\WRiSEOgT\|khMEh\|S{nBZ{kh[XRiMUCg{txO	MkLpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3M{i4OFAoRjJyNUO4PFQxRC:jPh?=
DMS114	MoG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknKTWM2OD14NECgcm0>	MmO0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OEK2OFMoRjJyNkiyOlQ{RC:jPh?=
H82	NELESWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTJ3MDDuUS=>	NVLMS4hIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2PFI3PDNpPkKwOlgzPjR\|PD;hQi=>
H146	NGKxd5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXTTWM2OD1\|NTDuUS=>	M2f3PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNkiyOlQ{Lz5{ME[4NlY1OzxxYU6=
H526	NUPKc\|dWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PFZWlEPTB;NEiwJI5O	Mlu5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OEK2OFMoRjJyNkiyOlQ{RC:jPh?=
KM-H2	M3zLO2Z2dmO2aX;uJGF{e2G7	Mk\CNeKh\|ryP	MXqwMlI2NTR6IHi=	M{\RR2ROW09?	MWrhZ5RqfmG2ZYOgUmYuc0J?	NEWyTmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi4NFExPyd-MkC4PFAyODd:L3G+
L428	M2n3WmZ2dmO2aX;uJGF{e2G7	MmDyNeKh\|ryP	M{\XS\|AvOjVvNEigbC=>	MnzPSG1UVw>?	MVvhZ5RqfmG2ZYOgUmYuc0J?	Mn3nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6OECxNFcoRjJyOEiwNVA4RC:jPh?=
HD-LM2	M{LjSGZ2dmO2aX;uJGF{e2G7	MXixxsDPxE1?	MVewMlI2NTR6IHi=	NXHIVlN4TE2VTx?=	MYfhZ5RqfmG2ZYOgUmYuc0J?	NGHhXoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi4NFExPyd-MkC4PFAyODd:L3G+
KM-H2	M4PRW2Z2dmO2aX;uJGF{e2G7	MmPKNE42NzFizszN	MkXDNlQwPDhiaB?=	NWDFS\|Z[TE2VTx?=	NEL6XVh2eHKnZ4XsZZRmeyCWTl[t{tEh\G:\|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=>	NXLWb45qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4PFAyODdpPkKwPFgxOTB5PD;hQi=>
L428	MXHGeY5kfGmxbjDBd5NigQ>?	NH\tUZoxNjVxMTFOwG0>	NGT2O4czPC92ODDo	M{XJZmROW09?	M1qyOZVxemWpdXzheIV{KFSQRj5OtUBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5	M2HrelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEiwNVA4Lz5{MEi4NFExPzxxYU6=
HD-LM2	MXHGeY5kfGmxbjDBd5NigQ>?	M{KyVFAvPS9zIN88US=>	MWiyOE81QCCq	NWj1TIJoTE2VTx?=	NH[zdm92eHKnZ4XsZZRmeyCWTl[t{tEh\G:\|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh6MEGwO{c,OjB6OECxNFc9N2F-
KM-H2	M{[1WWZ2dmO2aX;uJGF{e2G7	MUSxxsDPxE1?	NVf4Oo9IOjRxNEigbC=>	MkLESG1UVw>?	NUT4Z5ZM\G:5boLl[5Vt[XSnczDYTWFRNCCjY4TpeoF1\WRiY3HzdIF{\XNiOTDhcoQhOw>?	NGfqc\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi4NFExPyd-MkC4PFAyODd:L3G+
L428	M1vaZmZ2dmO2aX;uJGF{e2G7	NITuWVgyyqEQvF2=	NUfae3VHOjRxNEigbC=>	MVrEUXNQ	MWfkc5dvemWpdXzheIV{KFiLQWCsJIFkfGm4YYTl[EBk[XOyYYPld{A6KGGwZDCz	NE\ySHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi4NFExPyd-MkC4PFAyODd:L3G+
HD-LM2	NVTvTYUxTnWwY4Tpc44hSXO\|YYm=	NG[0c3cyyqEQvF2=	Ml\6NlQwPDhiaB?=	NV25W2ZCTE2VTx?=	MUXkc5dvemWpdXzheIV{KFiLQWCsJIFkfGm4YYTl[EBk[XOyYYPld{A6KGGwZDCz	M2PSdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEiwNVA4Lz5{MEi4NFExPzxxYU6=
KM-H2	MVHBdI9xfG:\|aYOgRZN{[Xl?	NWnQV41EOC5zL{CuOU8yKM7:TR?=	MVm0PEBp	Moq3SG1UVw>?	MVTpcoR2[2W\|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7	Mo\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6OECxNFcoRjJyOEiwNVA4RC:jPh?=
L428	NFH4WZNCeG:ydH;zbZMhSXO\|YYm=	NFTmUm4xNjFxMD61M\|Eh\|ryP	MWi0PEBp	NEDxO\|hFVVOR	NWjPbGszcW6mdXPld{BieG:ydH;zbZMh\G:\|ZTDk[ZBmdmSnboTsfS=>	M{XBcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEiwNVA4Lz5{MEi4NFExPzxxYU6=
HD-LM2	MnfuRZBweHSxc3nzJGF{e2G7	MXywMlEwOC53L{Gg{txO	M{n4elQ5KGh?	NX\1dVczTE2VTx?=	NVjYSoUzcW6mdXPld{BieG:ydH;zbZMh\G:\|ZTDk[ZBmdmSnboTsfS=>	M4q0SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEiwNVA4Lz5{MEi4NFExPzxxYU6=
KM-H2	M2fue2Z2dmO2aX;uJGF{e2G7	M1raXVAvOS1{IN88US=>	NFPuVHQzPCCqwrC=	M2TremROW09?	NYHhUXdwe2ixd4OgZYNmfHmuYYTpc44hd2ZiaHnzeI9v\SB\|IHHu[EB2eHKnZ4XsZZRqd25ib3[geIhmKGOnbHygZ5lkdGVicnXneYxifG:{eTDwdo91\WmwIICyNS=>	NHy4W3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi4NFExPyd-MkC4PFAyODd:L3G+
L428	MX;GeY5kfGmxbjDBd5NigQ>?	NU[0fZZjOC5zLUKg{txO	NUL1emdvOjRiaNMg	MXPEUXNQ	M{PRNZNpd3e\|IHHj[ZR6dGG2aX;uJI9nKGirc4TvcoUhOyCjbnSgeZBz\We3bHH0bY9vKG:oIITo[UBk\WyuIHP5Z4xmKHKnZ4XsZZRwenlicILveIVqdiCyMkG=	NV\DdYhJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4PFAyODdpPkKwPFgxOTB5PD;hQi=>
HD-LM2	NVnTVZJxTnWwY4Tpc44hSXO\|YYm=	MYOwMlEuOiEQvF2=	MWKyOEBpyqB?	NH\PXllFVVOR	NGfLN5N{cG:5czDhZ4V1gWyjdHnvckBw\iCqaYP0c45mKDNiYX7kJJVxemWpdXzheIlwdiCxZjD0bIUh[2WubDDjfYNt\SC{ZXf1cIF1d3K7IIDyc5RmcW5icEKx	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh6MEGwO{c,OjB6OECxNFc9N2F-
KM-H2	NIjtcoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MU[3NuKhcA>?	NF;wVYxFVVOR	MlHZTWM2OD1{Lki2JO69VQ>?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh6MEGwO{c,OjB6OECxNFc9N2F-
L428	NHjGS5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlX4O\|LDqGh?	NIPERWpFVVOR	NE[3c3BKSzVyPUGuPVYh\|ryP	MmX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6OECxNFcoRjJyOEiwNVA4RC:jPh?=
HD-LM2	NV\rSIo1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkLVO\|LDqGh?	M4f0bmROW09?	NGHDW45KSzVyPUGuPFgh\|ryP	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh6MEGwO{c,OjB6OECxNFc9N2F-
LP1	M362OmZ2dmO2aX;uJGF{e2G7	NGfKepIyyqEQvF2=	M1zQ[VI1KGh?		MVnlcohidmOnczC1MWFENWmwZIXj[YQhVUGJRT3BN{Bo\W6nIHX4dJJme3Orb36=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF5MUiyNUc,OjFzN{G4NlE9N2F-
ANBL6	M2T3SWZ2dmO2aX;uJGF{e2G7	NFjzWYwyyqEQvF2=	NVG4PIl[OjRiaB?=		MY\lcohidmOnczC1MWFENWmwZIXj[YQhVUGJRT3BN{Bo\W6nIHX4dJJme3Orb36=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF5MUiyNUc,OjFzN{G4NlE9N2F-
HMEC	M3zCdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2D2bmlEPTB;MUmg{txO	Mn7sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|MUe0OVUoRjJzM{G3OFU2RC:jPh?=
SW620	NIjNWFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTFizszN	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTNzN{S1OUc,OjF\|MUe0OVU9N2F-
SW48	NIDlTYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFqzUJBKSzVyPUCuPEDPxE1?	MlrZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|MUe0OVUoRjJzM{G3OFU2RC:jPh?=
HT-29	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MorMTWM2OD1yLkeg{txO	NX\0O5lbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzNVc1PTVpPkKxN\|E4PDV3PD;hQi=>
HCT15	M1G2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHuTWM2OD1yLkeg{txO	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTNzN{S1OUc,OjF\|MUe0OVU9N2F-
PAXF 1657L†	NGjYRm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnXSWM2OD1yLkOg{txO	NYizcmIyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO\|U3PzlpPkKxN\|c2Pjd7PD;hQi=>
PAXF 546L†	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTiSWM2OD1zLkWg{txO	M{fqSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{e1Olc6Lz5{MUO3OVY4QTxxYU6=
Panc-1	MnvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;hXFRGSzVyPUGuPEDPxE1?	M{jGeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{e1Olc6Lz5{MUO3OVY4QTxxYU6=
MiaPaca-2	M{HJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUn1[WhqTUN3ME2wMlYh\|ryP	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5NU[3PUc,OjF\|N{W2O\|k9N2F-
AsPC-1	NWTWWlUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHLSWM2OD1\|Lkmg{txO	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5NU[3PUc,OjF\|N{W2O\|k9N2F-
BxPC-3	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;ONWVEPTB;MT6xJO69VQ>?	MlnlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF\|N{W2O\|koRjJzM{e1Olc6RC:jPh?=
MMCs	M360W2Z2dmO2aX;uJGF{e2G7	NI[2bZMyyqEQvF2=	NYm2S\|ZQPi1{NDDo		M4fEUoRwe2VvZHXw[Y5l\W62bImgbY5pcWKrdIOgeIhmKHS{aX3leIh6dGG2aX;uJIxmfmWuIH;mJGg{NUt7IDjIN{1MQW2nMzm=	M2DSdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEWxN\|c5Lz5{NES1NVM4QDxxYU6=
MMCs	NX7vXYRKTnWwY4Tpc44hSXO\|YYm=	NHPkb\|UyyqEQvF2=	M2i3NVI1KGh?		MX3heYdu\W62czDncI9j[WxiYXPleJlt[XSrb36gcIV3\Wy\|IH;mJIhqe3SxbnWgTFMuUzlxMUSgLGg{NUt7L{G0ZYMqKGGwZDDIOE1MOTJiKFi0MWsyOmGlKR?=	NVrJWG86RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0OVE{PzhpPkK0OFUyOzd6PD;hQi=>
MMCs	M2TJbWZ2dmO2aX;uJGF{e2G7	MYSxxsDPxE1?	MlvGNlQhcA>?		NUnzd2J[cW6lcnXhd4V{KEiDVDDhZ5Rqfmm2eR?=	NXe1fWp1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0OVE{PzhpPkK0OFUyOzd6PD;hQi=>
MMCs	NXvxO3lxTnWwY4Tpc44hSXO\|YYm=	MlXRNE42NzFizszN	Mn7pNlQhcA>?		M3;EXZNpd3e\|IES1MYZwdGRic4TpcZVt[XSrb36gbY4h[0ePUDDs[ZZmdHN?	M{PMPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEWxN\|c5Lz5{NES1NVM4QDxxYU6=
MMCs	M2PhfWZ2dmO2aX;uJGF{e2G7	NUPRfZFrOSEQvH2=	NXLTWFgyOC12ODDo		NWnzUVZLcW6lcnXhd4V{KE6SUlGgdJJwfGWrbjDlfJBz\XO\|aX;uxsAzNjgkgKOzMlUh\m:uZB?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR3MUO3PEc,OjR2NUGzO\|g9N2F-
Panc1	MV;D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MkHqNeKh\|ryP	MWi3NuKhcA>?	MYrEUXNQ	MX\lcohidmOnczDn[Y1kcXSjYnnu[U1qdmS3Y3XzJINmdGxidnnhZoltcXS7IHTlZ5Jm[XOn	M1ztVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEeyPVQyLz5{NUi3Nlk1OTxxYU6=
Panc1	NH7EeYtCeG:ydH;zbZMhSXO\|YYm=	MVexxsDPxE1?	MYe3NuKhcA>?	MVHEUXNQ	NVr0e2Vie2Wwc3n0bZpmeyCSYX7jNUBk\WyuczDmc5Ih\2WvY3n0ZYJqdmVvaX7keYNm\CCjcH;weI9{cXN?	NHvXTJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi3Nlk1OSd-MkW4O\|I6PDF:L3G+
Panc1	NUG2cVVlTnWwY4Tpc44hSXO\|YYm=	MYmwMlUwOS9{LkWg{txO	MYC0PEBp	NE\OcVhFVVOR	MYjy[YR2[2W\|IHX4dJJme3Orb36gc4YhYkWEMTDvckBjd3SqIH3SUmEh[W6mIIDyc5RmcW5ibHX2[YzDqA>?	NFL6[2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi3Nlk1OSd-MkW4O\|I6PDF:L3G+
Panc1	NHjqcYlHfW6ldHnvckBCe3OjeR?=	M2LWS\|AvPS9zL{KuOUDPxE1?	MnTYOFghcA>?	MVPEUXNQ	NUDiSYFufXC{ZXf1cIF1\XNibXnSMVIxOw>?	M3TZZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEeyPVQyLz5{NUi3Nlk1OTxxYU6=
MOLP8	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NX3lT5V5PDhiaB?=		M3vOVGlEPTB;MD62xtEhOC5yNN88US=>	MkH3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOUG1NVgoRjJ4MEmxOVE5RC:jPh?=
T47D	NXH3emtlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M17tVlQ5KGh?		NE\V[lZKSzVyPUGuNVch\|ryP	NFriTIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO3PFA{QCd-Mk[zO\|gxOzh:L3G+
MCF7	M2DYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1jRXVQ5KGh?		MWXJR\|UxRTBwNkeg{txO	NVzzVld2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zO\|gxOzhpPkK2N\|c5ODN6PD;hQi=>
BT549	M1zKXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEjJXWs1QCCq		NVK2NY4{UUN3ME20MlM5KM7:TR?=	NFi4TlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO3PFA{QCd-Mk[zO\|gxOzh:L3G+
MDA-MB-231	M1ztb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1LucVQ5KGh?		MkTGTWM2OD1\|LkC0JO69VQ>?	NIfmXlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO3PFA{QCd-Mk[zO\|gxOzh:L3G+
HEK293	MoTtSpVv[3Srb36gZZN{[Xl?				M2q0UWlvcGmkaYTpc44hd2ZiSFTBR\|EhcW5iSFXLNlk{KGOnbHzzMEBKSzVyPUCuNVPPxE1?	MoPRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh\|MEi1OlMoRjF6M{C4OVY{RC:jPh?=
HEK293	M3TvPGZ2dmO2aX;uJIF{e2G7				M4\pO2lvcGmkaYTpc44hd2ZiSFTBR\|MhcW5iSFXLNlk{KGOnbHzzMEBKSzVyPUCuOlHPxE1?	M{[yU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6M{C4OVY{Lz5zOEOwPFU3OzxxYU6=
HCT116	M1LkbWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M4fF[lczKGi{cx?=		MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTBwMkpOwG0>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV5MEO2Okc,OTh3N{CzOlY9N2F-
HCT116	MmPUSpVv[3Srb36gZZN{[Xl?				MoOzTY5lfWO2aX;uJI9nKHB{MXPpdE94[WZzIIDyc5RmcW5iZYjwdoV{e2mxbjDpckBpfW2jbjDIR3QyOTZiY3XscJMhemWuYYTpeoUhfG9iTWOyO\|UtKEWFNUC9NE41Pc7:TR?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV5MEO2Okc,OTh3N{CzOlY9N2F-
Du145	MnjxRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NYH6fmlLPzJiaILz		MXXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKES3MUS1JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC54N988US=>	NIjhS3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW3NFM3Pid-MUi1O\|A{PjZ:L3G+
A549	MVfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		Mmf1O\|IhcHK\|		NVzXXFBlSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;MD65{txO	M3LMWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUewN\|Y3Lz5zOEW3NFM3PjxxYU6=
HCT116	MVrD[YxtKGO7Y3zlJIF{e2G7				NXOzR4ZIS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hUEOWMUG2JINmdGy\|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNk9OKHCqYYPlMEBGSzVyPEJOwG0>	NIfnVpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW3NFM3Pid-MUi1O\|A{PjZ:L3G+
T24	MUTGeY5kfGmxbjDhd5NigQ>?				MnH2TY5lfWO2aX;uJI9nKEh\|IHjpd5RwdmViYXPleJlt[XSrb36gbY4hcHWvYX6gWFI1KGOnbHzzJJJmdGG2aY\lJJRwKE2VMke1MEBGSzVyPUGuN\|jPxE1?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV5MEO2Okc,OTh3N{CzOlY9N2F-
HCT116	M4TUT2Fxd3C2b4Ppd{Bie3OjeR?=	MUOxJJVO			NXmwS4V5UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBJS1RzMU[gZ4VtdHNiYYSgNUB2VQ>?	NV24[JNlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1O\|A{PjZpPkG4OVcxOzZ4PD;hQi=>
HCT116	MoHGRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?				MUfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDifUBOXFRiYYPzZZktKEmFNUC9NE4{\|ryP	NHOyV4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGxOFMxPCd-MUmxNVQ{ODR:L3G+
HCT116	NUTLVHpsTnWwY4Tpc44h[XO\|YYm=		MVuxOkBpenN?		NVXITpZRUW6mdXP0bY9vKG:oIICyNXdCTjFxQ1nQNUBmgHC{ZYPzbY9vKGmwIHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{B1fWK3bHnuJIxmfmWuIHHmeIVzKDF4IHjyd{BjgSCudXPp[oVz[XOnIHHzd4F6NCCHQ{WwQVAvPs7:TR?=	NF;uPI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGxOFMxPCd-MUmxNVQ{ODR:L3G+
T24	NWDrbGdwTnWwY4Tpc44h[XO\|YYm=		M33oNVE3KGi{cx?=		NXLXUWU5UW6mdXP0bY9vKG:oIHjpd5RwdmViSESgbJlx\XKjY3X0fYxifGmxbjDpckBpfW2jbjDUNlQh[2WubIOgZYZ1\XJiMU[gbJJ{KGK7IHntcZVvd2Kub4T0bY5oNCCHQ{WwQFHPxE1?	NV[wcJdoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNVQ{ODRpPkG5NVE1OzB2PD;hQi=>
HCT116	MWjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?				NYXKTlJsSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25uIFnDOVA:OC5\|Md88US=>	NGTpUZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MU[1NFIzOSd-MkG2OVAzOjF:L3G+
H1299	MlO0RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?				M2fZTmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSEGyPVkh[2WubIOsJGlEPTB;MT60OO69VQ>?	NWi5OWt2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG2OVAzOjFpPkKxOlUxOjJzPD;hQi=>
HCT116	NGe5flJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=				NWnjUmFDSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMtKEmFNUC9NE4{Oc7:TR?=	NHXSdFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe0NlQ6Pid-MkG3OFI1QTZ:L3G+
Sf9	NXS4dJlzTnWwY4Tpc44h[XO\|YYm=		MYKyJIhzew>?		MUjJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVOxJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiaX7jeYJifGWmIH\vdkAzKGi{czD1d4lv\yCUSFvLMWFkKG[udX;yc4dmdmmlIIP1ZpN1emG2ZTygTWM2OD1yLkGwNu69VQ>?	NVPJeHpERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwNFkzODNpPkKzNFA6OjB\|PD;hQi=>
HCT116	M2XYeGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NEXjRXI4OiCqcoO=		MoT1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9NE4{OjgQvF2=	NHGz[XU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KwOlg3Pyd-MkOyNFY5Pjd:L3G+
A549	MUjDfZRwfG:6aXPpeJkh[XO\|YYm=		NFvwNHU4OiCqcoO=		NY\zb2xWS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVEvOjd7zszN	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJyNki2O{c,OjN{ME[4Olc9N2F-
MCF7	NXfsTGY3S3m2b4TvfIlkcXS7IHHzd4F6		NHfzWWE4OiCqcoO=		Mo\jR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPUSuPFA4\|ryP	M3XSNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkC2PFY4Lz5{M{KwOlg3PzxxYU6=
HCT116	M3HzSWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NETwOms4OiCqcoO=		M1fUemN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDifUBu\WG\|dYLpcoch[2WubIXsZZIhSVSSIHzleoVtKGGodHXyJFczKGi{czDifUBk\WyuLYTpeIVzKGeubzDhd5NigSxiSVO1NF0xNjgQvF2=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh{OUS4N{c,OjN6Mkm0PFM9N2F-
MCF7	MofaR5l1d3SxeHnjbZR6KGG\|c3H5		NI\Eb3g4OiCqcoO=		MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGK7IH3lZZN2emmwZzDj[YxtfWyjcjDBWHAhdGW4ZXygZYZ1\XJiN{KgbJJ{KGK7IHPlcIwufGm2ZYKg[4xwKGG\|c3H5MEBKSzVyPUGuNlbPxE1?	MoDCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6Mkm0PFMoRjJ\|OEK5OFg{RC:jPh?=
A549	MV3DfZRwfG:6aXPpeJkh[XO\|YYm=		NXzl[4hlPzJiaILz		NELQbYJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHL5JI1m[XO3cnnu[{Bk\WyudXzhdkBCXFBibHX2[Ywh[W[2ZYKgO\|IhcHK\|IHL5JINmdGxvdHn0[ZIh\2yxIHHzd4F6NCCLQ{WwQVEvPzQQvF2=	M2D6SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEK5OFg{Lz5{M{iyPVQ5OzxxYU6=
DU145	M1;1XmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MkHvO\|IhcHK\|		M4nHS2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHL5JI1m[XO3cnnu[{Bk\WyudXzhdkBCXFBibHX2[Ywh[W[2ZYKgO\|IhcHK\|IHL5JINmdGxvdHn0[ZIh\2yxIHHzd4F6NCCLQ{WwQVIvODcQvF2=	M{HJXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEK5OFg{Lz5{M{iyPVQ5OzxxYU6=
Jurkat	NUHDOFB6SXCxcITvd4l{KGG\|c3H5	MUSxJJRwKDFyIIXN	NGi2U3kzPCCqcoO=		NGnicopKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFr1dotifCClZXzsd{Bie3Onc4Pl[EBieyCSQWLQJINt\WG4YXflJIF1KDFidH:gNVAhfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	M3P6NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEK5OFg{Lz5{M{iyPVQ5OzxxYU6=
HeLa	NYX4NINNTnWwY4Tpc44h[XO\|YYm=	NETCPXoyKHSxIEGwJJVO	MV2yOEBpenN?		MmTCTY5pcWKrdHnvckBw\iCKRFHDJIlvKGi3bXHuJGhmVGFiY3XscJMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gTFNMQUGlIHzleoVtKGG2IEGgeI8hOTBidV2gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	NWDVe2MzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4Nlk1QDNpPkKzPFI6PDh\|PD;hQi=>
Jurkat	NXrNTZM3TnWwY4Tpc44h[XO\|YYm=	M33DVlEhfG9iMUCgeW0>	M3jQTFI1KGi{cx?=		NHLab5RKdmirYnn0bY9vKG:oIFjERWMhcW5iaIXtZY4hUnW{a3H0JINmdGy\|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKEh\|S{nBZ{Bt\X[nbDDheEAyKHSxIEGwJJVOKGGodHXyJFI1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	NUm3cXVrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4Nlk1QDNpPkKzPFI6PDh\|PD;hQi=>
High5	NFTR[npHfW6ldHnvckBie3OjeR?=		NWf1cWRCOyC2bzCyOEBpenN?		MoTwTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKRFHDNUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgbY5{\WO2IHjp[4g2KGOnbHzzJJV{cW6pIFHjMWx6ey2WeYKtUJl{KCincIPpcI9vNWGlZYT5cEkuSU2FIHHzJJN2[nO2cnH0[UBi\nSncjCzJJRwKDJ2IHjyd{BjgSCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVA:OC57Nd88US=>	NV3yWlBRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVUxOThpPkK0NFk2ODF6PD;hQi=>
HCT116	NWrINYZLSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M3PGT\|czKGi{cx?=		NGjtNXlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPUGuOVfPxE1?	M3zPV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEm1NFE5Lz5{NEC5OVAyQDxxYU6=
A549	NH\nUlhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NV7MXplWPzJiaILz		M{K2dWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTFwNkZOwG0>	M2LJeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEm1NFE5Lz5{NEC5OVAyQDxxYU6=
High5	NGjKO3BHfW6ldHnvckBie3OjeR?=		MX6zJJRwKDJ2IHjydy=>		NFjkOZVKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFjERWM{KGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgbIlocDViY3XscJMhfXOrbnegRYMuVHm\|LWT5dk1NgXNiKHXwd4ltd25vYXPleJltMS2DTVOgZZMhe3Wkc4TyZZRmKGGodHXyJFMhfG9iMkSgbJJ{KGK7IH\seY9z\XOlZX7j[UBie3OjeTygTWM2OD1zLk[3{txO	NVfOXnNzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVUxOThpPkK0NFk2ODF6PD;hQi=>
SNU16	NFz4PJhEgXSxdH;4bYNqfHliYYPzZZk>		M4P6[lczKGi{cx?=		MoHSR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV25WOTZiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjF2Mt88US=>	NYrGVYhPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NFU1PDZpPkK1PFA2PDR4PD;hQi=>
High5	Ml3vSpVv[3Srb36gZZN{[Xl?		M3XUclI1KGi{cx?=		M{\qZ2lvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iSFTBR\|Ih\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJIlve2WldDDIbYdpPSClZXzsd{B2e2mwZzDBZ{1NgXNvVInyMWx6eyBqZYDzbYxwdi2jY3X0fYwqNUGPQzDhd{B{fWK\|dILheIUh[W[2ZYKgNlQhcHK\|IHL5JIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3ME2wMlE4\|ryP	NInsS3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUiwOVQ1Pid-MkW4NFU1PDZ:L3G+
High5	NUiz[ndkTnWwY4Tpc44h[XO\|YYm=		MX[zJIhzew>?		M4HVPWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iSFTBR\|Mh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJIlve2WldDDIbYdpPSClZXzsd{B2e2mwZzDBZ{1NgXNvVInyMWx6eyBqZYDzbYxwdi2jY3X0fYwqNUGPQzDhd{B{fWK\|dILheIUh[W[2ZYKgN{BpenNiYomg[ox2d3Knc3PlcoNmKGG\|c3H5MEBKSzVyPUCuN\|bPxE1?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThyNUS0Okc,OjV6MEW0OFY9N2F-
High5	NELiSWVHfW6ldHnvckBie3OjeR?=		MmDCNlQhcHK\|		MmTNTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCKRFHDNUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgbY5{\WO2IFjp[4g2KGOnbHzzJJV{cW6pIFHjMWx6ey2WeYKtUJl{KCincIPpcI9vNWGlZYT5cEkuSU2FIHHzJJN2[nO2cnH0[UBi\nSncjCyOEBpenNiYomg[ox2d3Knc3PlcoNmKGG\|c3H5MEBKSzVyPUCuN\|nPxE1?	NF3nSYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUiwOVQ1Pid-MkW4NFU1PDZ:L3G+
HCT116	Mo\LR5l1d3SxeHnjbZR6KGG\|c3H5		M3rnT\|czKGi{cx?=		MUTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjN7Nt88US=>	NXy3SXdHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NFU1PDZpPkK1PFA2PDR4PD;hQi=>
SW620	MYTDfZRwfG:6aXPpeJkh[XO\|YYm=		MoCwO\|IhcHK\|		NWPxPJJDS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW1d4MkCgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1yLkSxPe69VQ>?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThyNUS0Okc,OjV6MEW0OFY9N2F-
MKN45	MUTDfZRwfG:6aXPpeJkh[XO\|YYm=		M2fmTVczKGi{cx?=		MlXPR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWtPPDViY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF0xNjZzzszN	NHLEU4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUiwOVQ1Pid-MkW4NFU1PDZ:L3G+
Hep3B	NFuwRVhEgXSxdH;4bYNqfHliYYPzZZk>		NFzzbpU4OiCqcoO=		MVLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZA{SiClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVAvQDJ\|zszN	MmC5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MEW0OFYoRjJ3OEC1OFQ3RC:jPh?=
HepG2	M36yO2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NH;kPYY4OiCqcoO=		M3r2cmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC56N{dOwG0>	M2nOW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEC1OFQ3Lz5{NUiwOVQ1PjxxYU6=
SNU5	MUfDfZRwfG:6aXPpeJkh[XO\|YYm=		Mom2O\|IhcHK\|		NW[0do83S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW06XNTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTFwMEC5{txO	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThyNUS0Okc,OjV6MEW0OFY9N2F-
A549	MWLDfZRwfG:6aXPpeJkh[XO\|YYm=		NHvnb4o4OiCqcoO=		MonYR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVIvODkQvF2=	NXHPSGl5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NFU1PDZpPkK1PFA2PDR4PD;hQi=>
SJSA1	MnLGR5l1d3SxeHnjbZR6KGG\|c3H5		Mn[yO\|IhcHK\|		NF70PXhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUUlODMTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTNwNkK0{txO	MkO3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MEW0OFYoRjJ3OEC1OFQ3RC:jPh?=
MHCC97H	MV\DfZRwfG:6aXPpeJkh[XO\|YYm=		MUK3NkBpenN?		NXfpPI1CS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUiFQ{m3TEBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPUSuOVY{\|ryP	NGLPbpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUiwOVQ1Pid-MkW4NFU1PDZ:L3G+
PANC1	NUPZc5VbS3m2b4TvfIlkcXS7IHHzd4F6		M2KyT\|czKGi{cx?=		NID4T\|REgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSU6FMTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxRTJ4Lke3OO69VQ>?	NGn5bmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUiwOVQ1Pid-MkW4NFU1PDZ:L3G+
U937	MoTLSpVv[3Srb36gZZN{[Xl?	Mlz3NVAhfU1?	MkfwNlQhcHK\|		MlTrTY5pcWKrdHnvckBw\iCKRFHDN{BqdiCqdX3hckBWQTN5IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lMVkh[WOndInsZZRqd25iYYSgNVAhfU1iaX7jeYJifGWmIH\vdkAzPCCqcoOgZpkhX2W\|dHXyckBjdG:2dHnu[{Bu\XSqb3S=	NILwR449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK4O\|MyOCd-Mk[yPFc{OTB:L3G+
PC3	MXHGeY5kfGmxbjDhd5NigQ>?	MX6xNEB2VQ>?	MXyyOEBpenN?		NF\kemhKdmirYnn0bY9vKG:oIFjERWM{KGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBpcXO2b37lJGg{KGy7c3nu[U06KGGlZYT5cIF1cW:wIHH0JFExKHWPIHnuZ5Vj[XSnZDDmc5IhOjRiaILzJIJ6KFenc4Tldo4h[myxdITpcochdWW2aH;k	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ6N{OxNEc,OjZ{OEezNVA9N2F-
U937	MU\GeY5kfGmxbjDhd5NigQ>?	NVX5fFhyOTBidV2=	NXvyeVZwOjRiaILz		NFO3cWZKdmirYnn0bY9vKG:oIFjERWMhcW5iaIXtZY4hXTl\|NzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[3mlbHnuJGUh\XiycnXzd4lwdiCrbjDheEAyOCC3TTDpcoN2[mG2ZXSg[o9zKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4T0bY5oKG2ndHjv[C=>	NUHw[4hjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yPFc{OTBpPkK2Nlg4OzFyPD;hQi=>
Sf9	M13QN2Z2dmO2aX;uJIF{e2G7		M3LxPFExKG2rboO=		NW\qemxVUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBnfWyuIHzlcod1cCCqdX3hckBENXSncn3pcoFtKE[OQVeteIFo\2WmIFjERWMyOSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHPlcIx{KHW\|aX7nJGJw[y2OeYOo[ZB{cWyxbj3BZ{kuSU2FIHHzJJN2[nO2cnH0[UBxemW2cnXheIVlKG[xcjCxNEBucW6\|IH\vcIxwf2WmIHL5JJN2[nO2cnH0[UBi\GSrdHnvckBjgSCobIXvdo9u\XS{aXOgcYV1cG:mLDDJR\|UxRTBwNUpOwG0>	NVTlN41ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1NFE2OTRpPkK4OVAyPTF2PD;hQi=>
TC32	NVrNVYlEeUiWUzDhd5NigQ>?				NHSydplyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVFOzNkBk\Wyucx?=	NGfhVZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	NUnQcY9ReUiWUzDhd5NigQ>?				NGD4bGpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?=	M37IUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	M3\UT5FJXFNiYYPzZZk>				MYfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	MlPWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	M4TZVpFJXFNiYYPzZZk>				MnvBdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN?	MoTLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	M3njXpFJXFNiYYPzZZk>				NGPF[XNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>	NETNUmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-37	NV:wbHR1eUiWUzDhd5NigQ>?				NXvz[IZoeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz	NFLzXGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB-EBc1	M17aNpFJXFNiYYPzZZk>				M1PQVZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz	NW\JSmF3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS	M4HMOpFJXFNiYYPzZZk>				MWPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy\|	NX[xN3ZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Saos-2	M1XUXJFJXFNiYYPzZZk>				NGPDenlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	NYrCVFBFeUiWUzDhd5NigQ>?				MlfKdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO=	NIDkWFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	NFzHOXlyUFSVIHHzd4F6				NXP4OlRNeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	NHHtcZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	MkfLdWhVWyCjc4PhfS=>				M3XQcJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?=	NYD3VmdMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12	M1TlRZFJXFNiYYPzZZk>				MmLRdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy\|	NGj1dIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh18	MXXxTHRUKGG\|c3H5				M1TZR5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEG4JINmdGy\|	MlH4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
OHS-50	NE\Ub2lyUFSVIHHzd4F6				MWnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	NGXSN3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
RD	NYXRNnE1eUiWUzDhd5NigQ>?				MYPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM>	NIfySYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MG 63 (6-TG R)	Mn\qdWhVWyCjc4PhfS=>				M4fqV5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?=	NEHIN209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
fibroblast cells	M4rj[pFJXFNiYYPzZZk>				MUTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5Ih[2:wdILvcEBJcCC5aXzkJJR6eGViZnnido9jdGG\|dDDj[Yxtew>?	MmTRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh41	NWHSe\|h3eUiWUzDhd5NigQ>?				Mnf6dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN?	MlG4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	M2OzUJFJXFNiYYPzZZk>				MVjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDBOlc{KGOnbHzzLS=>	NX7MfJFTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
DAOY	MV;xTHRUKGG\|c3H5				MUHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDERW9[KGOnbHzz	M2HFNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	NH;QdXJyUFSVIHHzd4F6				NYDCOFV5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	Mn20QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
U-2 OS	M3HhUJFJXFNiYYPzZZk>				NF\CcpByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBWNTJiT2OgZ4VtdHN?	MkjxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	MXPxTHRUKGG\|c3H5				NIju[o9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTTCClZXzsdy=>	Mk\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh18	MWDxTHRUKGG\|c3H5				MoP6dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVogyQCClZXzsdy=>	M1f2XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh30	NXTkeIJ1eUiWUzDhd5NigQ>?				NWnje4FUeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmh\|MDDj[Yxtew>?	M1f4fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Sf9	NVH5c29ETnWwY4Tpc44h[XO\|YYm=				M{nndmlvcGmkaYTpc44hSXO\|YYm6JGhFSUNiaX7obYJqfGmxbjDhd5NigXNid3Xy[UBx\XKob4Lt[YQh[nliUnXhZ5Rqd25iQnnvcI9ogSCFb4LwMkApVWGudnXyckwhWGFwKTD1d4lv\yCrc3;sZZRm\CCqdX3hckwhemWlb33ibY5idnRiZoXscE1t\W6pdHigTGRCSzFiYX7kJE03KG[{b32gZUBj[WO3bH;2bZJ2eyCneIDy[ZN{cW:wIIP5d5RmdSCrbjDT[lkh[2WubIOsJGlEPTB;MD6xNFLPxE1?	NEPvRXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzJ7OECvK\|5EcEWPQly8M4E,
HCT116	M3zwemFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MUe0PEBpenN?		MUPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME2xMlI1\|ryP	NFS0eXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzJ7OECvK\|5EcEWPQly8M4E,
MCF7	NX\UN2I1SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MmDlO\|IhcHK\|		M1jjVGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME2yMlQ6\|ryP	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|I6QDBxJ{7DbGVOSkx:L3G+
HeLa	Mn61RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MkDXOFghcHK\|		NVP3bGVISW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVMvOzMQvF2=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|I6QDBxJ{7DbGVOSkx:L3G+
HeLa	M1PWRmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NVHpO4xEPzJiaILz		M2T2bWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXMZUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME2zMlQz\|ryP	MkC0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlczQThyLze+R4hGVUKOPD;hQi=>
HCT116	Mn;2RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NXvRVHBmPzJiaILz		Ml;ORY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9N{42Oc7:TR?=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|I6QDBxJ{7DbGVOSkx:L3G+
HepG2	NEjKWXFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NV7zflFzPDhiaILz		MVrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyPUSuNFXPxE1?	NHPBdWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzJ7OECvK\|5EcEWPQly8M4E,
HepG2	NUHhXm9xSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M37PZlczKGi{cx?=		NUPTXpZNSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF01NjJ3zszN	NHHifW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzPzJ7OECvK\|5EcEWPQly8M4E,
HepG2	NX7Xd5lQSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MnLJNlQhcHK\|		MkPrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKZYDHNkBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgNlQhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME21Mlc6\|ryP	Mn6yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlczQThyLze+R4hGVUKOPD;hQi=>
A549	MYLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NYLjOWF{PzJiaILz		M4S2b2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3ME2xNU45P87:TR?=	NVjac243RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd{OUiwM{c,S2iHTVLMQE9iRg>?
A549	M4K2VWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		Mk\2OFghcHK\|		MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTB;MUSuOVfPxE1?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyO\|I6QDBxJ{7DbGVOSkx:L3G+
HCT116	M4LTV2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NWHxZ\|NUOjRiaILz		M4D1OmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkAzPCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVI6NjZ7zszN	M3;BSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFI4Ojl6MD:nQmNpTU2ETEyvZV4>
HeLa	NFvXTnpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NFPkPYUzPCCqcoO=		NH[5[mJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjlUIEh[2WubIOgZZN{\XO\|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFI1KGi{czDifUBOXFRiYYPzZZktKEmFNUC9OFMvQM7:TR?=	NUjHcZNqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjd{OUiwM{c,S2iHTVLMQE9iRg>?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Bad / Bid / Bak / Puma / Bax / Cleaved caspase-9 / Cleaved caspase-3 / Cleaved PARP; PubMed: 27551526 Cell Death Discov (a and b) DU-145 cells were treated with various doses of mocetinostat for 24 h. Western blotting was performed using the indicated antibodies. Ac-H3 / Ac-H4 / Ac-tubulin ; PubMed: 29186204 PLoS One Mocetinostat increased acetylated histone 3 and 4 in a time- and dose-dependent manner in LMS cells. Mocetinostat did not increase acetylated tubulin expression.	27551526 29186204
Immunofluorescence	E-cadherin / ZEB1 ; PubMed: 25872941 EMBO Mol Med Immunoblot and immunofluorescence showing that mocetinostat treatment (1 μM, 48 h) reduced ZEB1 expression and induced E-cadherin in Panc1. Expression of histone deacetylases was not altered by mocetinostat, but histone acetylation was induced. Scale bar 10 μm. Nanog / MHC ; PubMed: 26240433 Stem Cells Transl Med c-Kit+ cells were treated with 2 µM MOCE for 2 or 7 days, as indicated. The cells were double-labeled with anti-Nanog (green) and anti-αMHC (red) antibodies. Nuclei were stained with DAPI (blue). The upper right section of each panel shows the enlargement of the box-selected area. Scale bars = 20 µm.	25872941 26240433
Growth inhibition assay	Cell viability; PubMed: 26378038 Oncotarget B. Cells were treated with increasing concentrations of mocetinostat for 48 hours and assayed by the WST-1 cell viability assay. C. IC50 values were calculated by the GraphPad Prism software.	26378038

体内研究

在裸鼠中，MGCD0103明显抑制人类移植瘤的生长，及抑制肿瘤中组蛋白乙酰化诱导的的相关抗癌活性。MGCD0103每天口服处理携带移植的晚期 A549肿瘤的裸鼠，13天后，明显降低生长，这种作用存在剂量依赖性。MGCD0103与对照组相比，明显阻断肿瘤生长，且体重没有改变。此外, MGCD0103不会使WBC数降低，且耐受性很好。 MGCD0103 作用于许多其他人类移植瘤模型包括NSCLC H1437，是口服有效的。MGCD0103按80 mg/kg 剂量每天口服给药携带H1437肿瘤的动物，13天后，完全抑制肿瘤生长，且动物体重没有下降。 ^[1]MGCD0103降低肺动脉高血压症的效果比tadalafil好，tadalafil是治疗肺动脉高血压症的常规法，是一种血管舒张药。此外, MGCD0103提高肺动脉加速时间，且降低肺动脉的收缩，说明HDAC 抑制剂作用于肺血管具有很好效果。^[2]

激酶实验：^[1]	- 合并体外HDAC酶实验: 根据均相荧光释放法进行脱乙酰化酶活性测定。在实验buffer（包括25 mM HEPES，pH 为8.0, 137 mM NaCl, 1 mM MgCl₂, 2.7 mM KCl）中，纯化的重组HDAC酶和稀释成不同浓度的MGCD0103一起在室温下温育10分钟。加入底物Boc-Lys(ε-Ac)-AMC，在37^oC进一步温育。作用于不同亚型HDAC酶则底物浓度和温育时间都不同。加入胰蛋白酶室温下温育20分钟，脱乙酰化底物释放荧光。在360 , 470, 435 nm 波长处测定荧光信号。
细胞实验：^[1]	- 合并 Cell lines: 人类乳腺上皮细胞(HMEC)和人类包皮成纤维细胞(MRHF) Concentrations: 0-60 μM Incubation Time: 72小时 Method: 人类乳腺上皮细胞(HMEC)和人类包皮成纤维细胞(MRHF)接种在96孔板上，加入不同浓度MGCD0103，在含5% CO₂环境37^oC下温育72小时。加入3-(4,5-二甲基-2-噻唑基)-2,5-二苯基溴化四唑（MTT），最终浓度为0.5 mg/ml，和细胞一起温育4小时，然后加入同体积溶解buffer,buffer包含50% N,N-二甲基甲酰胺,及20% SDS(pH 为4.7)。温育过夜，在630 nm 处标记，在570 nm 处读数，测量溶解的染料。根据相关细胞系的标准生长曲线计算细胞的吸光值。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 携带H1437肿瘤的雌性CD-1裸鼠 Dosages: 80 mg/kg Administration: 口服处理 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	13 mg/mL (32.79 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 30% PEG400+0.5% Tween80+5% Propylene glycol	30mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Mocetinostat (MGCD0103) SDF

分子量	396.44
化学式	C₂₃H₂₀N₆O
CAS号	726169-73-9
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	MG0103

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2022-01-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04299113	Recruiting	Drug: Vinorelbine\|Drug: Mocetinostat	Rhabdomyosarcoma	Jonsson Comprehensive Cancer Center\|Mirati Therapeutics Inc.\|Phase One Foundation	May 14 2020	Phase 1
NCT02993991	Withdrawn	Drug: Mocetinostat\|Biological: Durvalumab	Squamous Cell Carcinoma Head And Neck\|Squamous Cell Carcinoma Mouth\|Resectable Squamous Cell Carcinoma of Oral Cavity	University Health Network Toronto\|Mirati Therapeutics Inc.\|AstraZeneca	October 10 2017	Phase 1
NCT02236195	Completed	Drug: Mocetinostat	Urothelial Carcinoma	Mirati Therapeutics Inc.	October 2014	Phase 2
NCT00666497	Terminated	Drug: Azacitidine\|Drug: MGCD0103	Acute Myeloid Leukemia (AML)\|Myelodysplastic Syndrome (MDS)	Mirati Therapeutics Inc.	June 2008	Phase 2
NCT00511576	Terminated	Drug: MGCD0103 & Docetaxel	Breast Cancer\|Lung Cancer\|Pulmonary Cancer\|Non-Small-Cell Lung Carcinoma\|Prostate Cancer\|Prostatic Cancer\|Gastric Cancer\|Stomach Cancer	Mirati Therapeutics Inc.	August 2007	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

选择性强的HDAC抑制剂

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
活性最高的HDAC抑制剂

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA批准的HDAC抑制剂

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
最新的HDAC抑制剂

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

研究领域

产品类型

定制您的化合物库

Mocetinostat (MGCD0103)

客户使用Selleck生产的Mocetinostat (MGCD0103)发表文献96篇：

产品安全说明书

HDAC抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Mocetinostat (MGCD0103) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2022-01-17)

技术支持

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品